WHITE PAPER
Following Rare Disease Patients Across Payer Transitions
A Real-World Data Perspective on Longitudinal Continuity for Research and Commercial Strategy
Executive Summary
Rare disease patients are statistically more likely to change payers across the course of their lives than typical commercially insured patients. Three structural forces drive this pattern:
- Most rare diseases manifest in childhood, frequently routing patients through Medicaid or the Children’s Health Insurance Program (CHIP)
- Severe progressive conditions trigger disability pathways into Medicare under age 65
- High treatment costs concentrate patient populations within Medicaid and Medicare Advantage
For health economics and outcomes research (HEOR), real-world evidence (RWE), and commercial functions in pharmaceutical and biotech organizations, these payer transitions are not edge cases. They are the rule.
Real-world data (RWD) sources that fail to maintain patient-level continuity across coverage events systematically undercount rare disease populations, fragment patient journeys, and weaken study designs that depend on continuous longitudinal observation.
This paper examines how rare disease populations move between payer types, the specific research and commercial implications of data discontinuity, and the structural properties of data sources that determine whether patients can be followed across the full arc of their care.
Inside, you’ll learn:
- Why rare disease patients experience payer transitions more frequently than other populations
- How payer transitions appear in RWD
- The implications for HEOR, RWE, and commercial strategy
- Why cross-payer patient continuity matters for longitudinal analyses
- Key considerations when evaluating data sources for rare disease work
